Asia Invests in Laboratory Tools for Medicinal Chemistry
News May 01, 2006
Radleys has announced sales of its parallel chemistry and laboratory reactor products have contributed to a 400% growth in its Asian business during 2004-5 and 2005-6.
Reflecting on the spectacular business growth, Mark Radley (Managing Director) commented, "In recent years a growing proportion of our traditional pharmaceutical and biotech industry customers in Europe and North America have started to relocate part of their R&D to Asia."
"Consequently we have increased our resource allocation to the region and have seen companies including SABIC, Nicholas Piramal, Altana, GVK, Syngene, Dr Reddys, Advinus and Torrent investing in technology such as the Carousel, GreenHouse and Lara product ranges, to enable them to either win contracts from US or European pharma/biotech companies or to develop their own R&D programs."
Tuberculosis (TB), an ancient and notoriously difficult disease to treat, has killed millions through the course of human history; and the antibiotics that have been used to fight the disease in recent history are becoming less and less effective. In the face of this reality, researcher Prof. Dennis Wright has improved upon a new way to thwart the tricky pathogen, mycobacterium tuberculosis.READ MORE
Researchers have solved the structures of the cancer-promoting enzymes USP25 and USP28, and identified significant differences in their activities. This knowledge provides the molecular basis for the development of new and highly specific anti-cancer drugs, with a low risk of side-effects.READ MORE